ADMA Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022
21 mars 2022 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., March 21, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA
07 mars 2022 16h05 HE
|
ADMA Biologics, Inc.
FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth Company positioned to meet or exceed target of 10 or more FDA-approved plasma collection centers by...
ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update
19 janv. 2022 07h00 HE
|
ADMA Biologics, Inc.
Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Inception Full Year 2021 Preliminary Unaudited Total...
ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SC
18 janv. 2022 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla. and GOOSE CREEK, S.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated...
ADMA Biologics Adopts Limited Duration Stockholder Rights Plan
21 déc. 2021 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and...
ADMA Biologics Provides Update on Global Intellectual Property Portfolio
09 déc. 2021 07h00 HE
|
ADMA Biologics, Inc.
Extends Existing U.S. Patent with Granted European Patent for Treatment and Prevention of S. Pneumococcal Infections with a Hyperimmune Globulin Reinforces Existing and Pending IP that Provides for...
ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors
17 nov. 2021 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 17, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC
16 nov. 2021 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla. and MYRTLE BEACH, S.C., Nov. 16, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical...
ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments
10 nov. 2021 16h01 HE
|
ADMA Biologics, Inc.
Generated Record Total Revenues of $20.7 Million in the Third Quarter 2021, a 101% Increase Over Third Quarter 2020 Achieved First-Time Positive Gross Profit Narrowed Net Losses...
ADMA Biologics to Report Third Quarter 2021 Financial Results on November 10, 2021
03 nov. 2021 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...